Physician profile
Megan E Witherow
NPI 1356748693
$2,578.03
in general payments reported to CMS, 2019-2025
7 companies · $755 in 2025
The $755 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.12 · 2022: $952 · 2023: $372 · 2024: $453 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $763.75 | 2022-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Shockwave Medical, INC | $539.95 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $399.78 | 2022-2025 | Endurant Iis, Spiderfx, In.Pact Admiral |
| W. L. Gore & Associates, INC. | $346.66 | 2022-2025 | Gore Viabahn Endoprosthesis, Gore Viabahn Vbx Balloon Expandable Endo, Gore Viabahn Endoprosthesis With Heparin |
| Boston Scientific Corporation | $292.65 | 2025 | Enroute Transcarotid Neuroprotection System, Enhance Transcarotid Peripheral Access Kit, Enroute Transcarotid Stent |
| Abbott Laboratories | $138.72 | 2021-2022 | |
| Stryker Corporation | $96.52 | 2025 | Flowtriever |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Witherow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.